Chinese biotechnology company Vazyme recently attended Medica 2021 in Germany, one of the world’s largest events for the medical sector, to accelerate the expansion of its international business. At the event, Vazyme showcased its latest 3-in-1 virus testing solutions, the SARS-CoV-2 Ag & FLU A/B Rapid Test and the SARS-CoV-2, Influenza A/B RT-QPCR Detection Kit, and both attracted great attention from visitors. The booth attracted more than 500 visitors, including representatives and distributors from Germany, the Czech Republic, Switzerland, and Bulgaria, with whom we have reached a preliminary cooperation agreement.
“While rapidly responding to the pandemic and developing an entire series of industry-leading COVID-19 testing solutions that enable rapid and accurate results, we have also continued broader efforts to grow our business presence around the world,” stated Dr. Tang Bo, the Co-Founder, and GM of Medical Division of Vazyme. “EU is an important market for us and we are dedicated to customer service with extensive local operations installed to better serve our local customers.”.
As the world prepares to reopen, high-quality, rapid, and holistic diagnostic solutions for COVID -19 will play a critical role in the fight against the virus. Vazyme has developed its effective screening tools -the SARS-CoV-2 & FLU A/B RT-QPCR Detection Kit for nucleic acid detection and the SARS-CoV-2 & FLU A/B Ag Rapid Test – for the simultaneous detection of three virus types that cause COVID -19, influenza A and influenza B.
The company receives CE labeling approval for its SARS-CoV-2 Antigen Detection Kit (for self-testing) and the kit will soon be available as a home test in European markets. The antigen detection kit is capable of real-time detection of multiple variants of COVID -19 including the delta variant, the most infectious form of the coronavirus.
By following the simple instructions, you can self-test from the comfort of your own home or any other location. The rapid and portable testing solution helps prevent asymptomatic transmission, curbs the spread of coronavirus in the community and reduces pressure on local health systems by quickly identifying individuals with the highest potential for infection.
The performance of Vazyme’s COVID -19 test products has been fully validated by several accredited European laboratories, including the Paul Ehrlich Institute, Locus Medicus, Alabiso Lab, and others. Vazyme continuously partners with leading global academic institutions, laboratories, and healthcare providers in overseas markets to optimize localized sales and distribution networks and ensure the company’s global users receive the testing and care they need.
As a technological innovator, Vazyme considers its continuous investment in the research and development of innovative solutions a top priority. This ensures the company’s ability to develop new products with innovative technologies and continue to build a comprehensive product portfolio to meet the diverse needs of its global customers.
